Kantarjian et al53 assessed the efficacy and basic safety of dasatinib, as when compared with imatinib, for the first-line cure of CML-CP. 5 hundred and nineteen patients with freshly diagnosed CML-CP were being randomly assigned to acquire dasatinib in a dose of a hundred mg the moment everyday (259 individuals) https://bernardn777jct7.bmswiki.com/user